Can it get any worse for Novartis’ U.S. stock? The Swiss company said Tuesday that del-desiran, part of a recent acquisition, reached the end of the line in a trial for a rare neuromuscular disease. The drugmaker’s U.S.-listed shares slumped 13% to $139.01 Tuesday. Continue Reading
We show the main point publicly. Create a free account to continue reading the full article, save it, discuss it, and connect it with market and OSINT context.